Phase 1 cancer drug abstract lands ASCO 2026 slot in Chicago The Phase 1 study is testing the CDH6-targeting ADC in advanced solid tumors, including platinum-resistant ovarian cancer, ahead of the May 29-June 2 meeting.

#NXTC NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

www.stocktitan.net/news/NXTC/next-cure-and-...

NextCure Provides Business Update and Reports Full Year 2025 Financial Results NextCure (Nasdaq: NXTC) provided a business update and reported full-year 2025 results on March 5, 2026. Key clinical milestones include SIM0505 Phase 1 dose escalation data expected Q2 2026 and initiation of a Phase 1 dose optimization study in platinum resistant ovarian cancer in Q2 2026. LNCB74 enrollment continues with a trial update planned H2 2026. Financials: $41.8M cash at year-end and net loss of $55.8M for 2025; company expects runway into H1 2027 through SIM0505 proof-of-concept.

#NXTC NextCure Provides Business Update and Reports Full Year 2025 Financial Results

www.stocktitan.net/news/NXTC/next-cure-prov...

NextCure Provides Business Update  NextCure (NASDAQ: NXTC) provided a business update on Jan 23, 2026, reporting clinical progress for two ADC programs and a preliminary year-end cash position.SIM0505 (CDH6 ADC): Phase 1 dose-escalation data from U.S. and China cohorts are expected in Q2 2026; company is adding sites and increasing drug supply to start dose optimization in H1 2026. LNCB74 (B7-H4 ADC): dose escalation expanded into higher cohorts with prioritization of high B7-H4 breast and gynecological cancer patients; proof-of-concept timing delayed to a trial update in 2H 2026. Financials: preliminary cash and equivalents approx $41.8M, expected to fund operations into 1H 2027.

#NXTC NextCure Provides Business Update 

www.stocktitan.net/news/NXTC/next-cure-prov...

Trade Alerts, Monday November 24, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Mon Nov 24th - #YDES #HSAI #VOR #SLRX #NXTC #MXL #ENLV #CLLS #BLFY #AEHL #MAGN #GNK #CMDB #BFLY - More: crystalequityresearch.com/trade-alerts... - #smallcap

#NXTC NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

www.stocktitan.net/news/NXTC/next-cure-anno...

#NXTC NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/NXTC/next-cure-prov...

Leading Indicators, Wednesday October 22, 2025 – Crystal Equity Research

Small-cap stocks overbought with declining relative strength, Wed Oct 22nd - #STOK #SEED #REKR #ORKA #OCS #NXTC #EGAN #CRBP #LBRT #HQL #VCIC - More: crystalequityresearch.com/leading-indi... - #smallcap

NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States NextCure (Nasdaq: NXTC) and Simcere Zaiming announced expansion of the ongoing Phase 1 trial of SIM0505 (CDH6 ADC) into the United States on Oct 16, 2025. The first U.S. patient was dosed at a mid-tier dose level where multiple responses have been observed, while dose escalation continues in China.NextCure holds an exclusive global license (excluding Greater China) for SIM0505. The trial evaluates safety, tolerability, pharmacokinetics and efficacy in advanced solid tumors; current data are described as well tolerated with a favorable safety profile. Both companies expect to accelerate enrollment and aim to present proof-of-concept data in 1H 2026.

#NXTC NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

www.stocktitan.net/news/NXTC/next-cure-and-...

NextCure (NXTC) Q2 Loss Widens 71% | The Motley Fool

#NXTC #343f2a90-1a0a-4acb-a052-04d7dc6e59f3 #data-news

Origin | Interest | Match

Original post on benzinga.com

Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease NextCure Inc. (NASDAQ: NXTC) surged by 44.87% in after-hours trading on Thursday,...

#Equities #NXTC #why #it's #moving #Markets #NXTC #Equities […]

[Original post on benzinga.com]

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Mon Jun 16th - #RCON #NXTC #LZMH #KLXE #CREG #PRO #NINE #AVAL #SRPT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Mon Jun 16th - #RCON #NXTC #LZMH #KLXE #CREG #PRO #NINE #AVAL #SRPT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Two professionals, one in a lab coat, shake hands in a biotechnology lab setting with digital analytics screens in the background, symbolizing a strategic partnership involving NextCure.

#NXTC jumped 8% premarket after announcing a partnership with Simcere Zaiming to develop SIM0505, a novel antibody-drug conjugate targeting CDH6 in solid tumors. U.S. Phase 1 trial expected to begin in Q3 2025.
#NextCureInc
prismmarketview.com/nextcure-ral...

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 NextCure (NXTC) and Simcere Zaiming announced a strategic partnership for SIM0505, a novel antibody-drug conjugate targeting CDH6 for solid tumors. NextCure gains global rights excluding Greater China, where Simcere Zaiming retains rights. SIM0505 is currently in Phase 1 trials in China, with U.S. trials expected to begin in Q3 2025. Initial Phase 1 data is anticipated in H1 2026. The deal includes access to Simcere's proprietary linker and TOPOi payload for NextCure's novel target ADC. SIM0505 features increased tumor binding compared to competitors and demonstrates robust anti-tumor activity. The agreement includes up to $745M in potential payments to Simcere Zaiming, including upfront payment, milestones, and tiered royalties up to double digits on net sales outside Greater China.

#NXTC NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

www.stocktitan.net/news/NXTC/next-cure-and-...

Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? NextCure completes Phase 1 cohort for B7-H4 ADC cancer therapeutic, reduces net loss to $55.7M, with cash runway into H2 2026. Pipeline expands beyond oncology.

#NXTC NextCure Provides Business Update and Reports Full Year 2024 Financial Results

www.stocktitan.net/news/NXTC/next-cure-prov...

NextCure Advances Cancer Treatment: First Patient Dosed in LNCB74 Phase 1 Trial NextCure initiates Phase 1 clinical trial of LNCB74, a novel B7-H4-targeting antibody-drug conjugate, following FDA clearance. Study targets multiple cancer types.

#NXTC NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

www.stocktitan.net/news/NXTC/next-cure-anno...

Top 60 pickleball 🥒 pros now average $260,000 annually—rivaling other pro sports. Where does tennis stand?

A full breakdown coming in the next Tennis & Money newsletter!

Follow NXTCourt and Subscribe

#TennisAndMoney #PickleballVsTennis #RacquetSports #NXTC

🎾 Tennis Earnings in 2024: A Tale of Two Worlds 💸
ATP Top 100 Avg: $8.85M
Rank 401–500 Avg: $48,881

The gap is staggering. We break it down for you. All tours, all numbers.
📩 Dive deeper in the next Tennis & Money newsletter. Follow and subscribe

#PrizeMoney #TennisBusiness #TennisEconomics #NXTC

🎾💡 What If Tennis Changed the Game?

What if players signed long-term contracts, teams competed like LIV Golf, or a draft system reshaped the sport?

Explore bold ideas in the What If… series in next week’s Tennis & Money.

📨 Subscribe now and rethink tennis.

#NXTC #TennisAndMoney #SportsBusiness

🎾 2025 Tennis Outlook: Prize Money & Planning 📊

💡Big changes:
✅ ITF prize money up 26% ($14.6M total).
✅ UTR adds $11M for global pro events.
✅ ATP Tour expands Masters & ATP 500s.

🗓 All details in next NXTC Tennis & Money Newsletter
👉 Subscribe now!

#TennisAndMoney #NXTC #TennisOutlook

NextCure's Cancer Drug LNCB74 Secures FDA IND Approval for Phase 1 Clinical Trials NextCure advances its innovative B7-H4-targeting antibody-drug conjugate to clinical trials following FDA approval, marking a milestone in cancer treatment development.

#NXTC NextCure Announces Acceptance of IND Application for LNCB74

#StockMarket #stocks #investing

www.stocktitan.net/news/NXTC/next-cure-anno...

#NXTC NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

www.stocktitan.net/news/NXTC/next-cure-to-p...